New ways to reduce blood clots by targeting fibrinogen levels
Novel mechanisms to limit thrombosis by decreasing fibrinogen or suppressing fibrin matrix formation
This study is looking at ways to lower the risk of blood clots by focusing on a protein called fibrinogen, and it aims to find new treatments that help your body break down clots more easily while still keeping your bleeding under control.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-11030788 on NIH RePORTER |
What this research studies
This research investigates how to decrease the risk of blood clots by targeting fibrinogen, a protein that plays a key role in clot formation. The approach involves using innovative techniques to either lower fibrinogen levels in the blood or suppress the formation of the fibrin matrix, which is the structure that makes up blood clots. By creating a less dense fibrin network, the study aims to enhance the body's ability to break down clots while still allowing for normal bleeding control. This could lead to new treatments for various thrombotic conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals at high risk for thrombotic diseases, such as those with elevated fibrinogen levels or certain chronic inflammatory conditions.
Not a fit: Patients who do not have issues related to blood clotting or those with conditions that do not involve fibrinogen may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly reduce the risk of life-threatening blood clots.
How similar studies have performed: Previous research has shown promise in targeting fibrinogen and fibrin matrix formation, indicating that this approach could be effective.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Flick, Matthew J. — Univ of North Carolina Chapel Hill
- Study coordinator: Flick, Matthew J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.